Swipe Left For English News
中国上海,
2024年6月14日
全球领先的合同研究、开发和生产CRDMO服务公司药明生物（WuXi Biologics, 2269.HK）宣布其凭借在可持续发展方面的卓越表现，入选明晟公司（MSCI）2024年环境、社会和公司治理（ESG）领导者指数。这是公司连续第二年被纳入该指数。
MSCI是全球领先的投资调研公司，为机构投资者提供股票指数和投资组合绩效分析。MSCI ESG领导者指数旨在反映行业内ESG表现卓越的企业。在MSCI ESG调研和评级体系支持下，该指数衡量企业对于ESG风险和机遇的管理水平并筛选出符合条件的企业。2023年，药明生物凭借在气候变化、公司治理、人才发展及产品安全与质量等关键议题上的出色表现，获得了AAA评级。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们很荣幸再次入选MSCI ESG领导者指数，这是对我们在ESG领域持续精进的肯定和认可。药明生物始终将可持续发展视为业务发展战略的基石。再次入选MSCI ESG领导者指数，展现了我们聚焦公司愿景和使命，并全面布局和高效执行ESG战略所取得的成绩。我们将再接再厉，推进可持续发展能力向纵深发展，为全球合作伙伴及社会公众创造和释放更大价值。
药明生物在联合国可持续发展目标的指导下，沿着可持续发展道路稳步向前。2023年，公司入选标普道琼斯可持续发展世界指数和新兴市场指数，并在标普全球企业可持续发展评估中被评为全球可持续发展领导者。此外，公司自2021年起入选富时社会责任指数，彰显了全球ESG评级机构和机构投资者对公司ESG卓越表现的广泛认可。
推荐阅读
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年12月底，药明生物帮助客户研发和生产的综合项目高达698个，其中包括24个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Named to MSCI ESG Leaders Indexes for Second Consecutive Year
Shanghai,
June 14, 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been named to the 2024 MSCI ESG Leaders Indexes. This marks the second consecutive year the company has been included in the indexes for its outstanding sustainability performance.
MSCI, a leading investment research firm, provides stock indexes and portfolio performance analytics to institutional investors. Its ESG Leaders Indexes are designed to represent the performance of companies with high ESG ratings relative to their sector peers. The index suite utilizes MSCI's award-winning ESG Research and ESG Ratings to identify companies that have demonstrated an ability to manage their ESG risks and opportunities and are therefore eligible for inclusion. In 2023, WuXi Biologics received an AAA rating from MSCI for outstanding performance in Key Issues of Climate Change, Corporate Governance, Talent Development, and Product Safety & Quality, on its rating scale from AAA (Leaders) to CCC (Laggards).
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very proud to be included again in the MSCI ESG Leaders Indexes. WuXi Biologics regards sustainability as the cornerstone of our business development, and being recognized by MSCI as an ESG industry leader underscores the success of our comprehensive ESG strategy – in alignment with the company's vision and mission – as well as the effective implementation of our ESG approaches. Moving forward, we will continue to enhance our sustainability capabilities for the common good of the global community.
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development. In 2023, it was named to the Dow Jones Sustainability™ World Index and Emerging Markets Index, identified as a sustainability leader by S&P Global through its annual Corporate Sustainability Assessment (CSA). Since 2021, the company has been selected as a constituent company of the FTSE4Good Index Series, demonstrating strong ESG practices measured against globally recognized standards.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
